Subject: A survey to assess the usage pattern of Clobazam in the management of epilepsy in India
Epilepsy is a chronic noncommunicable disease of the brain, characterized by recurrent seizures, which are brief episodes of involuntary movement that may involve a part of the body (partial) or the entire body (generalized) and are sometimes accompanied by loss of consciousness and control of bowel or bladder function.
Intractable epilepsy is defined as occurrence of two or more seizures per month for a period of more than 2 years despite using two or more AEDs in maximum tolerated (2 x 2 x 2) dose.
Clobazam, a long-acting benzodiazepine, is a medication that may prove to be both efficacious and tolerable in this treatment-resistant group; has prolonged activity due to its active metabolite, N-desmethylclobazam, and, unlike typical 1,4- benzodiazepines, is a 1,5-benzodiazepine conferring increased specificity for the GABA A receptors with a2 rather than a1 subunits.
Study has showed that clobazam is effective and well-tolerated as a long-term adjunctive therapy for adults with drug-resistant epilepsy; efficacy in off-label use is similar to that in LGS.
This survey is conducted to understand usage pattern of clobazam in the management of epilepsy in India.
As you will be spending some extra time to give your feedback on the questionnaire based on your clinical experience, we offer to pay you by cheque a professional fee of Rs {{$contractAmount}}, on receiving the completed Survey Questionnaire Form from you.
We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})